切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2023, Vol. 17 ›› Issue (03) : 151 -156. doi: 10.3877/cma.j.issn.1674-0807.2023.03.004

论著

伴人类免疫缺陷病毒感染乳腺癌患者的临床病理特征与预后的相关性研究
吴茜, 邓力, 练士贤, 张华, 江颖, 张宏伟()   
  1. 200083 上海市公共卫生临床中心普外科
    200032 上海,复旦大学附属中山医院普外科
  • 收稿日期:2022-07-29 出版日期:2023-06-01
  • 通信作者: 张宏伟

Relationship between clinicopathological characteristics and prognosis of HIV-infected breast cancer patients

Qian Wu, Li Deng, Shixian Lian, Hua Zhang, Ying Jiang, Hongwei Zhang()   

  1. Department of General Surgery, Shanghai Public Health Center, Shanghai 200083, China
    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
  • Received:2022-07-29 Published:2023-06-01
  • Corresponding author: Hongwei Zhang
引用本文:

吴茜, 邓力, 练士贤, 张华, 江颖, 张宏伟. 伴人类免疫缺陷病毒感染乳腺癌患者的临床病理特征与预后的相关性研究[J/OL]. 中华乳腺病杂志(电子版), 2023, 17(03): 151-156.

Qian Wu, Li Deng, Shixian Lian, Hua Zhang, Ying Jiang, Hongwei Zhang. Relationship between clinicopathological characteristics and prognosis of HIV-infected breast cancer patients[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(03): 151-156.

目的

研究人类免疫缺陷病毒(HIV)感染乳腺癌患者的临床病理特征、治疗现状及预后情况。

方法

采用回顾性队列研究方法,收集2016年8月至2022年1月于上海市公共卫生临床中心就诊的19例伴HIV感染乳腺癌患者临床资料(HIV组),以2016年11月至2021年5月同医院收治的174例非HIV乳腺癌患者作为研究对照(非HIV组)。通过倾向性评分匹配(PSM)按1∶2匹配后得到38例患者作为对照组。应用Kaplan-Meier法绘制生存曲线,采用Log-rank检验比较2组患者的DFS和OS。采用Cox比例风险回归模型进行预后的单因素及多因素分析。

结果

19例HIV感染乳腺癌患者中位随访时间为24个月。PSM前相较于HIV组,非HIV组患者激素受体阳性率、Ki-67低表达率、肿瘤分期为0、Ⅰ、Ⅱ期和区域淋巴结无转移率的患者比例均更高(P=0.034、0.048、0.026;χ2=4.499,P=0.034)。PSM后,2组患者的基线资料比较无统计学差异,2组患者DFS和OS比较,差异具有统计学意义(χ2=8.295,P=0.004;χ2=12.759,P<0.001)。单因素分析发现激素受体状态与DFS相关(HR=0.115,95%CI:0.013~0.991,P=0.049),HIV感染与DFS及OS均相关(HR=6.101,95%CI:1.510~24.657,P=0.004;HR=17.682,95%CI:2.049~152.565,P<0.001)。多因素分析发现HIV感染与DFS及OS均相关(HR=7.891,95%CI:1.715~36.322,P=0.008;HR=37.796,95%CI:2.338~611.103,P=0.011)。

结论

HIV感染的乳腺癌患者预后较差。

Objective

To study the clinicopathological characteristics, treatment and prognosis of HIV-infected breast cancer patients.

Methods

We conducted a retrospective cohort analysis of 19 HIV-infected breast cancer patients (HIV-infected group) in the Department of General Surgery, Shanghai Public Health Clinical center from August 2016 to January 2022. Another 174 breast cancer patients who were not infected by HIV (non-HIV-infected group) admitted in the same hospital from November 2016 to May 2021 served as controls. By propensity score matching (PSM) at 1∶2, 38 cases were obtained from non-HIV-infected group. The Kaplan-Meier method was applied to develop survival curves, and the Log-rank test was used to compare disease-free survival (DFS) and overall survival (OS) between two groups. The Cox proportional risk regression model was used for univariate and multivariate analyses.

Results

The median follow-up time was 24 months. All patients were treated with standardized HARRT therapy. Before PSM, compared with the HIV-infected group, the non-HIV-infected group showed higher rates of hormonal receptor(HR) positivity, low Ki-67 expression, 0-Ⅱ stage tumor and no metastasis in axillary lymph nodes (P=0.034, 0.048, 0.026; χ2=4.499, P=0.034). After PSM, there was no significant difference in the baseline data between two groups, but the DFS and OS presented a significant difference (χ2=8.295, P=0.004; χ2=12.759, P<0.001). Univariate Cox analysis showed that HR expression was related to DFS (HR=0.115, 95%CI: 0.013-0.991, P=0.049), and HIV infection was related to both DFS and OS (HR=6.101, 95%CI: 1.510-24.657, P=0.004; HR=17.682, 95%CI: 2.049-152.565, P<0.001). Multivariate analysis showed that HIV infection was related to both DFS and OS (HR=7.891, 95%CI: 1.715-36.322, P=0.008; HR=37.796, 95%CI: 2.338-611.103, P=0.011).

Conclusion

HIV-infected breast cancer patients have a poor prognosis.

表1 57例乳腺癌患者预后影响因素的Cox回归分析变量赋值表
表2 HIV感染组和非HIV感染组乳腺癌患者临床病理特征比较
图1 HIV感染和非HIV感染组乳腺癌患者的生存曲线 a图为患者的无瘤生存曲线;b图为患者的总生存曲线注:无复发生存率,χ2=8.295,P=0.004;总生存率,χ2=12.759,P<0.001
表3 57例乳腺癌患者总生存率和无瘤生存率影响因素的单因素分析
表4 57例乳腺癌患者总生存率和无瘤生存率影响因素的多因素分析
[1]
Ceccarelli M, Venanzi RE, Marino MA, et al. Non-AIDS defining cancers: a comprehensive update on diagnosis and management[J]. Eur Rev Med Pharmacol Sci, 202024(7):3849-3875.
[2]
Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy[J]. Cold Spring Harb Perspect Med, 20122(4):a7161.
[3]
Coghill AE, Shiels MS, Suneja G, et al. Elevated cancer-specific mortality among HIV-infected patients in the United States[J]. J Clin Oncol, 201533(21):2376-2383.
[4]
Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV~infected persons compared with the general population in the United States, 1992-2003[J]. Ann Intern Med, 2008148(10):728-736.
[5]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin. 202171(3):209-249.
[6]
Jiang Z, Li J, Chen J, et al. Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022 [J]. Transl Breast Cancer Res20223: 13.
[7]
覃亚勤,罗凤,黎彦君,等. 艾滋病合并恶性肿瘤住院患者疾病谱分析[J/CD]. 新发传染病电子杂志20227(1):39-42.
[8]
Brandão M, Bruzzone M, Franzoi MA, et al. Impact of HIV infection on baseline characteristics and survival of women with breast cancer[J]. Aids, 202135(4):605-618.
[9]
Bense RD, Sotiriou C, Piccart-Gebhart MJ, et al. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer[J]. J Natl Cancer Inst, 2017109(1): djw192.
[10]
Cubasch H, Joffe M, Hanisch R, et al. Breast cancer characteristics and HIV among 1,092 women in Soweto, South Africa[J]. Breast Cancer Res Treat, 2013140(1):177-186.
[11]
Coghill AE, Han X, Suneja G, et al. Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base[J]. Cancer, 2019125(16):2868-2876.
[12]
Robbins HA, Pfeiffer RM, Shiels MS, et al. Excess cancers among HIV-infected people in the United States[J]. J Natl Cancer Inst., 2015107(4):dju503.
[13]
郑莹,吴春晓,张敏璐. 乳腺癌在中国的流行状况和疾病特征[J]. 中国癌症杂志201323(8):561-569.
[14]
Singh SN, Zhu Y, Chumsri S, et al. Outcomes and chemotherapy-related toxicity in HIV-infected patients with breast cancer [J]. Clin Breast Cancer201414(2):e53-e59.
[15]
Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, no-Hodgkin lymphoma[J]. Cancer, 200191(1):155-163.
[16]
Levine AM. Evaluation and management of HIV-infected women[J]. Ann Intern Med, 2002136(3):228-242.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[9] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[10] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[13] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[14] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要